SG11201406336YA - Stem cell microparticles - Google Patents
Stem cell microparticlesInfo
- Publication number
- SG11201406336YA SG11201406336YA SG11201406336YA SG11201406336YA SG11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA SG 11201406336Y A SG11201406336Y A SG 11201406336YA
- Authority
- SG
- Singapore
- Prior art keywords
- stem cell
- cell microparticles
- microparticles
- stem
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/088—Coculture with; Conditioned medium produced by cells of the nervous system neural stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1205972.1A GB201205972D0 (en) | 2012-04-03 | 2012-04-03 | Stem cell product |
GBGB1212848.4A GB201212848D0 (en) | 2012-07-19 | 2012-07-19 | Stem cell product |
GBGB1302468.2A GB201302468D0 (en) | 2013-02-12 | 2013-02-12 | Stem cell product |
PCT/GB2013/050879 WO2013150303A1 (en) | 2012-04-03 | 2013-04-03 | Stem cell microparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406336YA true SG11201406336YA (en) | 2014-11-27 |
Family
ID=48095915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406336YA SG11201406336YA (en) | 2012-04-03 | 2013-04-03 | Stem cell microparticles |
Country Status (11)
Country | Link |
---|---|
US (2) | US20150079046A1 (en) |
EP (2) | EP3470073A1 (en) |
JP (5) | JP6450673B2 (en) |
KR (1) | KR101993027B1 (en) |
CN (1) | CN104321062B (en) |
AU (1) | AU2013245406B2 (en) |
BR (1) | BR112014024541A2 (en) |
CA (1) | CA2868506C (en) |
ES (1) | ES2691296T3 (en) |
SG (1) | SG11201406336YA (en) |
WO (1) | WO2013150303A1 (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2683389B1 (en) | 2011-03-11 | 2017-05-03 | Children's Medical Center Corporation | Methods and compositions relating to mesenchymal stem cell exosomes |
US20150164955A1 (en) * | 2012-07-19 | 2015-06-18 | Reneuron Limited | Stem cell microparticles |
EP3498701B1 (en) | 2012-12-21 | 2023-02-22 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
WO2014125277A1 (en) * | 2013-02-12 | 2014-08-21 | Reneuron Limited | Method of producing microparticles |
EP3003290B1 (en) | 2013-06-05 | 2021-03-10 | AgeX Therapeutics, Inc. | Compositions for use in the treatment of wounds in mammalian species |
US20160193252A1 (en) * | 2013-08-14 | 2016-07-07 | Reneuron Limited | STEM CELL MICROPARTICLES AND miRNA |
GB201317887D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product |
CN103740645A (en) * | 2013-12-06 | 2014-04-23 | 山西医科大学 | Preparation of neural stem cell-derived Exosomes, and application of neural stem cell-derived Exosomes in nervous system diseases |
JP6343671B2 (en) * | 2013-12-12 | 2018-06-13 | サムスン ライフ パブリック ウェルフェア ファウンデーション | Method for promoting the generation of stem cell-derived exosomes using thrombin |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
WO2015138878A1 (en) * | 2014-03-13 | 2015-09-17 | Research Institute At Nationwide Children's Hospital, Inc. | Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes |
JP6295341B2 (en) | 2014-03-18 | 2018-03-14 | サムソン ライフ パブリック ウェルフェア ファウンデーション | Composition for treating brain inflammatory disease comprising stem cell-derived exosome as an active ingredient |
CN103940998B (en) * | 2014-05-04 | 2016-04-20 | 山东大学 | The application of the early diagnosis marker that serum microRNA shifts as hepatocellular carcinoma |
DK3145493T3 (en) | 2014-05-18 | 2022-10-31 | Childrens Medical Center | METHODS AND COMPOSITIONS RELATING TO EXOSOMES |
KR101593797B1 (en) * | 2014-05-22 | 2016-02-12 | 가톨릭대학교 산학협력단 | Pharmaceutical composition for treating or preventing diabetes mellitus comprising mir-137 |
KR101721492B1 (en) * | 2014-05-26 | 2017-03-30 | 한국생명공학연구원 | Pharmaceutical composition comprising expression or activity inhibitors of NDRG3 for the prevention and treatment of cancer |
WO2015200851A1 (en) * | 2014-06-27 | 2015-12-30 | Inarian Neurodiagnostics, Llc | Method for enriching cns-derived exosomes |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
ES2831298T3 (en) | 2014-11-07 | 2021-06-08 | Exocobio Inc | Composition that includes exosomes derived from stem cells to whiten the skin or improve wrinkles |
WO2016072821A1 (en) * | 2014-11-07 | 2016-05-12 | 한양대학교 에리카산학협력단 | Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement |
WO2016083500A1 (en) * | 2014-11-27 | 2016-06-02 | Med Cell Europe Ag | Secretomes and method for producing secretomes |
WO2016082882A1 (en) * | 2014-11-27 | 2016-06-02 | Med Cell Europe Ag | Secretomes and method for producing secretomes |
ES2774456T3 (en) | 2014-12-30 | 2020-07-21 | Cell Cure Neurosciences Ltd | RPE cell populations and methods of cell generation |
WO2016186987A1 (en) * | 2015-05-15 | 2016-11-24 | Trustees Of Dartmouth College | Biomarker micrornas and method for determining tumor burden |
WO2017001649A1 (en) * | 2015-07-02 | 2017-01-05 | Med Cell Europe Ag | Secretomes and method for producing secretomes |
CN107849535B (en) | 2015-08-03 | 2022-11-22 | 国立大学法人大阪大学 | Exosomes derived from mesenchymal stem cells |
US20170121685A1 (en) * | 2015-11-02 | 2017-05-04 | Tigenix S.A.U. | Mesenchymal stem cell-derived exosomes and their uses |
US20170119682A1 (en) * | 2015-11-02 | 2017-05-04 | Tigenix, S.A.U. | Mesenchymal stem cell-derived exosomes and their uses |
US11857575B2 (en) | 2015-11-02 | 2024-01-02 | Takeda Pharmaceutical Company Limited | Mesenchymal stem cell-derived exosomes and their uses |
CN108697740A (en) | 2015-11-18 | 2018-10-23 | 佐治亚大学研究基金会 | The outer vesica of nerve cell |
CN106729750A (en) * | 2015-11-20 | 2017-05-31 | 昆山彭济凯丰生物科技有限公司 | Method and medicine and their application of high fat of blood, fatty liver, type-II diabetes and losing weight are treated by miR-183 |
WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
CN109153968A (en) * | 2016-04-12 | 2019-01-04 | 联合细胞Ev股份公司 | Extracellular vesica (EV) is separated from biologicfluid sample |
WO2017191234A1 (en) * | 2016-05-06 | 2017-11-09 | Unicyte Ev Ag | Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia |
TWI601741B (en) | 2016-07-11 | 2017-10-11 | 財團法人國家衛生研究院 | Method of producing exosomes by using ep4-antagonist to induce exosomes releasing from stem cells and the use thereof |
WO2018033911A1 (en) | 2016-08-14 | 2018-02-22 | Ramot At Tel-Aviv University Ltd. | Mesenchymal cell-derived exosomes to treat neurological disorders |
CN106367419A (en) * | 2016-10-10 | 2017-02-01 | 徐州医科大学 | Antisense oligonucleotide with neuroprotective effect, medicine composition and application thereof |
CN107858424B (en) * | 2016-11-24 | 2021-05-25 | 南华大学 | Application of miRNA-4731-3p as primary lung cancer diagnosis marker |
EP3600151A4 (en) * | 2017-05-05 | 2021-01-13 | Capricor, Inc. | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
CN107243012B (en) * | 2017-05-25 | 2020-01-24 | 江苏大学 | Application of exosomes-loaded miR-93-5p in treatment of rheumatoid arthritis |
KR102056172B1 (en) * | 2017-12-06 | 2019-12-16 | 주식회사 디자인셀 | Composition for treating or preventing arthritis comprising culture solution of stem cell-derived exosome |
EP3731789A4 (en) * | 2017-12-29 | 2021-09-08 | Cell Cure Neurosciences Ltd. | Retinal pigment epithelium cell compositions |
KR102096150B1 (en) | 2018-01-05 | 2020-04-02 | 재단법인 아산사회복지재단 | Composition for Improving Skin Conditions, or Preventing or Treating Skin Diseases comprising Induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells pre-treated with Interferon-gamma, and Exosomes derived therefrom |
CN112236131A (en) * | 2018-03-29 | 2021-01-15 | 技术研究及发展基金有限公司 | Vesicles comprising PTEN inhibitors and uses thereof |
EP3773519A4 (en) * | 2018-04-06 | 2021-12-29 | Wisconsin Alumni Research Foundation | Structured nanocoatings for the stabilization of pluripotent stem cell media components |
KR102111025B1 (en) * | 2018-06-05 | 2020-05-15 | 고려대학교 산학협력단 | Cosmetic Composition for Anti-aging or Anti-wrinkles Comprising Neural Stem Cell Conditioned Medium and Method for Preparing the Same |
CN109276575B (en) * | 2018-07-23 | 2020-02-07 | 海南医学院 | Application of miR-9 in preparation of medicine for treating acute coronary syndrome |
CN112566626A (en) | 2018-08-10 | 2021-03-26 | 欧姆尼斯普兰特有限公司 | Extracellular vesicles for inhalation |
CN113015794A (en) * | 2018-10-12 | 2021-06-22 | 兰诺龙有限公司 | Induced pluripotent cells comprising controllable transgenes for conditional immortalization |
CN109234381B (en) * | 2018-10-22 | 2021-06-18 | 云南省玉溪市人民医院 | Application of miR-2682-5p as renal fibrosis marker |
KR102320800B1 (en) * | 2018-10-25 | 2021-11-02 | 사회복지법인 삼성생명공익재단 | Stem cell-derived microvesicles with enhanced efficacy, use thereof and method for enhancing efficacy |
US11351119B2 (en) | 2018-10-25 | 2022-06-07 | Samsung Life Public Welfare Foundation | Stem cell-derived microvesicles with enhanced efficacy, use thereof, and method for enhancing efficacy |
CN109680058A (en) * | 2019-01-10 | 2019-04-26 | 华中科技大学同济医学院附属协和医院 | Application and kit of the miR-101 level detection in diabetic microvascular complication diagnostic reagent |
EP4219686A1 (en) * | 2019-06-10 | 2023-08-02 | Brexogen Inc. | Composition for promoting production of stem cell-derived exosomes and increasing stemness |
KR102159914B1 (en) * | 2019-07-30 | 2020-09-24 | 주식회사 엑소코바이오 | New method for producing exosomes and its application |
US20210052641A1 (en) * | 2019-08-23 | 2021-02-25 | United Therapeutics Corporation | Pre-conditioned extracellular vesicles and methods of production |
CN110564682B (en) * | 2019-09-30 | 2021-04-02 | 陕西中鸿科瑞再生医学研究院有限公司 | Method for large-scale production of human adipose-derived mesenchymal stem cell exosomes |
GB201919021D0 (en) | 2019-12-20 | 2020-02-05 | Reneuron Ltd | Nucleic acid constructs for delivering polynucleotides into exosomes |
EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
KR102319735B1 (en) * | 2020-04-28 | 2021-11-01 | 건국대학교 산학협력단 | A Method for Obtaining Extracellular Vesicles from 3-Dimensional Cultured Stem Cells |
KR102184428B1 (en) * | 2020-05-25 | 2020-11-30 | 주식회사 씨케이엑소젠 | Method for preparing exosomes from mesenchymal stem cells and culture solution and culture solution produced from the same |
CN111850047B (en) * | 2020-07-28 | 2022-08-12 | 枣庄学院 | miR-16 and miR-30c combined expression vector and construction method and application thereof |
KR102284304B1 (en) | 2020-11-05 | 2021-08-02 | 주식회사 타임바이오 | Isolation method of progenitor cells using cold shock and method for producing exosome using these progenitor cells |
WO2022114724A1 (en) * | 2020-11-27 | 2022-06-02 | (주)엑셀세라퓨틱스 | Medium composition for producing exosome with high efficacy and high purity |
WO2022204487A1 (en) * | 2021-03-26 | 2022-09-29 | Duke University | Systems and methods for exosome delivery of micrornas for cellular reprogramming |
US11613734B2 (en) | 2021-06-11 | 2023-03-28 | Fullstem Co., Ltd. | Method of collecting for exosome |
GB202114441D0 (en) | 2021-10-08 | 2021-11-24 | Reneuron Ltd | Proteins and extracellular vesicles |
KR20230129667A (en) * | 2022-03-02 | 2023-09-11 | 서울대학교병원 | Composition containing exosomes extracted from mesenchymal stem cells for preventing or treating retinal degeneration disease |
JP7371975B1 (en) | 2022-09-27 | 2023-10-31 | セルソース株式会社 | Method for producing extracellular vesicles and composition containing extracellular vesicles |
WO2024089632A1 (en) * | 2022-10-26 | 2024-05-02 | Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) | Composition of extracellular vesicles and uses thereof |
CN116426648B (en) * | 2023-03-27 | 2024-03-08 | 艾一生命科技(广东)有限公司 | miRNA combination for identifying stem cell exosomes and qRCR primer thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US5753506A (en) | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6468794B1 (en) | 1999-02-12 | 2002-10-22 | Stemcells, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
CA2399434C (en) | 2000-02-11 | 2010-10-19 | The Schepens Eye Research Institute, Inc. | Isolation and transplantation of retinal stem cells |
PL1758986T3 (en) | 2004-06-09 | 2016-03-31 | Univ Court Univ Of Edinburgh | Neural stem cells |
EP1645626B1 (en) | 2004-09-30 | 2007-09-12 | Reneuron Limited | Cell line |
WO2006087233A2 (en) * | 2005-02-21 | 2006-08-24 | Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. | Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells |
US20070264712A1 (en) * | 2006-01-10 | 2007-11-15 | Theradigm, Inc. | Expansion and differentiation of neural stem cells under low oxygen conditions |
JP5718648B2 (en) | 2008-02-22 | 2015-05-13 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) | Mesenchymal stem cell particles |
WO2010062706A2 (en) * | 2008-10-30 | 2010-06-03 | Caris Mpi, Inc. | Methods for assessing rna patterns |
KR101067742B1 (en) * | 2009-01-05 | 2011-09-28 | 서울대학교산학협력단 | Exosome derived from Human Neural Stme Cells with Immunomodulatory Effect and Immunomodulator comprising the same |
WO2010119256A1 (en) * | 2009-04-17 | 2010-10-21 | Isis Innovation Limited | Composition for delivery of genetic material |
EP2448595B1 (en) * | 2009-07-02 | 2017-06-14 | ITH Immune Therapy Holdings AB | Exosome based treatment of cancer |
WO2011062244A1 (en) * | 2009-11-18 | 2011-05-26 | Kuroda Masahiko | Carrier, method for producing same, and applications of same |
WO2011069100A2 (en) * | 2009-12-04 | 2011-06-09 | Duke University | Microrna and use thereof in identification of b cell malignancies |
US9297007B2 (en) * | 2010-05-28 | 2016-03-29 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | miRNAs involved in the blood brain barrier function |
GB201011589D0 (en) | 2010-07-09 | 2010-08-25 | Reneuron Ltd | Therapeutic cells |
EP3412282A1 (en) * | 2011-06-02 | 2018-12-12 | The Regents of the University of California | Membrane encapsulated nanoparticles and method of use |
WO2013124816A2 (en) * | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | Generation of neural stem cells and motor neurons |
-
2013
- 2013-04-03 KR KR1020147030788A patent/KR101993027B1/en active IP Right Grant
- 2013-04-03 US US14/390,010 patent/US20150079046A1/en not_active Abandoned
- 2013-04-03 CN CN201380025532.4A patent/CN104321062B/en active Active
- 2013-04-03 EP EP18190631.4A patent/EP3470073A1/en active Pending
- 2013-04-03 BR BR112014024541A patent/BR112014024541A2/en not_active Application Discontinuation
- 2013-04-03 WO PCT/GB2013/050879 patent/WO2013150303A1/en active Application Filing
- 2013-04-03 CA CA2868506A patent/CA2868506C/en active Active
- 2013-04-03 ES ES13716352.3T patent/ES2691296T3/en active Active
- 2013-04-03 JP JP2015503941A patent/JP6450673B2/en active Active
- 2013-04-03 AU AU2013245406A patent/AU2013245406B2/en active Active
- 2013-04-03 EP EP13716352.3A patent/EP2833893B1/en active Active
- 2013-04-03 SG SG11201406336YA patent/SG11201406336YA/en unknown
-
2018
- 2018-09-28 JP JP2018183862A patent/JP6644851B2/en active Active
-
2019
- 2019-08-28 US US16/554,388 patent/US20190388475A1/en active Pending
-
2020
- 2020-01-08 JP JP2020001568A patent/JP2020072718A/en active Pending
-
2022
- 2022-05-02 JP JP2022075866A patent/JP2022115954A/en active Pending
-
2024
- 2024-03-13 JP JP2024039106A patent/JP2024073546A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20150004822A (en) | 2015-01-13 |
US20150079046A1 (en) | 2015-03-19 |
US20190388475A1 (en) | 2019-12-26 |
AU2013245406A1 (en) | 2014-10-02 |
WO2013150303A1 (en) | 2013-10-10 |
KR101993027B1 (en) | 2019-09-30 |
CA2868506C (en) | 2023-10-24 |
JP2019013234A (en) | 2019-01-31 |
JP6644851B2 (en) | 2020-02-12 |
JP6450673B2 (en) | 2019-01-09 |
JP2022115954A (en) | 2022-08-09 |
JP2015513906A (en) | 2015-05-18 |
EP3470073A1 (en) | 2019-04-17 |
EP2833893A1 (en) | 2015-02-11 |
CA2868506A1 (en) | 2013-10-10 |
AU2013245406B2 (en) | 2017-07-20 |
CN104321062A (en) | 2015-01-28 |
EP2833893B1 (en) | 2018-08-29 |
ES2691296T3 (en) | 2018-11-26 |
CN104321062B (en) | 2018-09-25 |
JP2024073546A (en) | 2024-05-29 |
JP2020072718A (en) | 2020-05-14 |
BR112014024541A2 (en) | 2017-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201500329WA (en) | Stem cell microparticles | |
SG11201406336YA (en) | Stem cell microparticles | |
HK1211623A1 (en) | Cell lines | |
HK1209295A1 (en) | Concentrator | |
SG11201503867WA (en) | Structure | |
EP2857651A4 (en) | Coolant-control valve | |
AU347859S (en) | Battery | |
AU346864S (en) | Battery | |
EP2824749A4 (en) | Laminated-structure battery | |
SI2758523T1 (en) | Stromal stem cells | |
EP2911230A4 (en) | Cell | |
EP2939306A4 (en) | Battery | |
EP2831949A4 (en) | Sodium-oxygen cells | |
IL237228B (en) | Stem cell enhancing therapeutics | |
EP2888513A4 (en) | Pulse-width-regulating valve | |
PL2867530T3 (en) | Tappet | |
GB201319035D0 (en) | Spolier structure | |
EP2821614A4 (en) | Valve | |
SI2904319T1 (en) | Thermostic valve | |
EP2939294A4 (en) | Battery | |
EP2863459A4 (en) | Flat cell | |
HUP1300640A2 (en) | Belt-mounting structure | |
EP2871919A4 (en) | Structure | |
HUP1200436A2 (en) | Valve arrangement | |
GB201203255D0 (en) | Valve |